NeoGenomics (NEO) has drawn fresh attention after raising full year 2026 revenue guidance to US$797 million to US$803 million and reporting first quarter results that included higher sales and a smaller net loss.

Despite the raised 2026 revenue guidance and new Epic Aura integration, the share price, now at US$8.86, shows mixed momentum. This is reflected in a 10.75% 1 month share price return, a 24.66% year to date share price decline, and a 15.21% 1 year total shareholder return.

If this kind of healthcare data integration has your attention, it could be a good moment to look at other potential opportunities through our screener of 35 healthcare AI stocks

With the stock at US$8.86, a 69% discount to the average analyst price target and a history of mixed returns, you have to ask: is this a mispriced cancer testing specialist, or is the market already factoring in future growth?

Most Popular Narrative: 37.6% Undervalued

With NeoGenomics last closing at $8.86 against a narrative fair value of $14.19, the current price sits well below what this widely followed view considers reasonable.

The commercial launch of PanTracer, a comprehensive liquid biopsy panel for therapy selection, is set to enhance NeoGenomics' competitiveness and capture greater share in the rapidly growing NGS and liquid biopsy segment, supporting revenue acceleration and higher average unit prices (AUP) through 2025 and beyond.

Curious what kind of revenue climb, margin shift, and future earnings multiple need to line up for that fair value to make sense? The narrative ties together growth in oncology testing demand, expanding product coverage, and a premium profit multiple that is well above the broader US Healthcare sector. The key is how those moving parts are expected to compound over several years.

Result: Fair Value of $14.19 (UNDERVALUED)

However, this hinges on pharma demand stabilising and new products like PanTracer avoiding setbacks, since any funding pressure or launch delays could quickly challenge that positive view.

Another Take: Multiples Point to a Richer Price Tag

The fair value narrative leans on future earnings power, but the current P/S ratio of 1.5x tells a different story. It sits above the US Healthcare sector at 1.2x and above peer averages at 1x, as well as above the 1.2x fair ratio the market could eventually gravitate toward. For investors, that premium hints at less margin for error than the 37.6% undervalued story suggests. Which signal feels more convincing to you?

Next Steps

With such different signals around NeoGenomics, are you leaning more cautious or optimistic, and how quickly do you want to firm up that view? Before you decide, take a moment to review the 1 important warning sign

Looking for more investment ideas?

If you are serious about sharpening your portfolio, do not stop at a single stock story. Use targeted screeners to quickly surface fresh, high conviction ideas.

• Spot potential bargains early by scanning screener containing 25 high quality undiscovered gems that combine quality fundamentals with limited market attention.
• Strengthen your defensive side by focusing on companies in the 72 resilient stocks with low risk scores that score well on resilience and lower volatility.
• Target robust balance sheets by filtering for companies in the solid balance sheet and fundamentals stocks screener (46 results) that pair financial strength with underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.